Wedbush analyst Liana Moussatos raised her price target for Relypsa to $75 after the FDA approved its treatment of hyperkalemia, Veltassa. The stock is trading down 19%, or $3.13, to $13.02. The approved label places no limitations on the potential use of Veltassa in the acute/non-emergency setting as adjunct therapy or in the chronic setting, Moussatos tells investors in a research note. She believes the label's box warning indicating potential drug-drug interactions is "easily addressable" and "a minor issue." The analyst keeps an Outperform rating on the name.